文献速递血栓与止血

围手术期口服艾曲泊帕对比静脉注射免疫球蛋白治疗免疫性血小板减少症患者:一项非劣效性、多中心、随机试验

Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.
PubMed 文献 · Lancet Haematol · 2020-01-01

在加拿大8家学术医院开展的随机开放标签非劣效性试验,纳入74例免疫性血小板减少症患者,比较围手术期口服艾曲泊帕50mg与静脉注射免疫球蛋白1g/kg或2g/kg。意向性分析显示艾曲泊帕组围手术期血小板目标达标率79%(30/38)vs 免疫球蛋白组61%(22/36),绝对风险差17.8%,非劣效性P=0.005。艾曲泊帕组发生2例严重不良事件(1例治疗相关肺栓塞、1例眩晕),免疫球蛋白组5例严重不良事件均为手术并发症。

要点

  • 围手术期口服艾曲泊帕50mg在达到血小板目标方面非劣效于静脉注射免疫球蛋白。
  • 意向性分析达标率艾曲泊帕组79%(30/38)vs 免疫球蛋白组61%(22/36),绝对风险差17.8%。
  • 艾曲泊帕组发生1例治疗相关肺栓塞,作者认为艾曲泊帕可能增加血栓风险。

核心结论

  • 艾曲泊帕是免疫性血小板减少症围手术期治疗中静脉注射免疫球蛋白的有效替代方案。
  • 但艾曲泊帕治疗可能增加血栓风险。
  • 选择何种治疗取决于患者偏好、资源限制、成本和个体风险特征。

研究设计与样本

  • 随机、开放标签、非劣效性、多中心试验,在加拿大8家学术医院开展。
  • 纳入年龄≥18岁、原发性或继发性免疫性血小板减少症患者,大手术前血小板计数<100×10^9/L或小手术前<50×10^9/L。
  • 随机前2周内使用过静脉注射免疫球蛋白或4周内使用过血小板生成素受体激动剂者不允许入组。
  • 2013年6月5日至2019年3月7日筛查92例患者,随机分配74例(80%):艾曲泊帕组38例,免疫球蛋白组36例。
  • 随机序列由计算机随机数生成器产生,隐藏并按中心和手术类型(大或小)分层;中心研究统计师对治疗分配设盲。

主要发现

  • 中位随访50天(IQR 49-55)。
  • 意向性分析:围手术期血小板目标达标艾曲泊帕组30/38(79%)vs 免疫球蛋白组22/36(61%),绝对风险差17.8%,95%CI单侧下限0.4%,非劣效性P=0.005。
  • 符合方案分析:达标艾曲泊帕组29/37(78%)vs 免疫球蛋白组20/32(63%),绝对风险差15.9%,95%CI单侧下限-2.1%,非劣效性P=0.009。
  • 艾曲泊帕组发生2例严重不良事件:1例治疗相关肺栓塞和1例眩晕。
  • 免疫球蛋白组发生5例严重不良事件(心房颤动、胰腺炎、外阴疼痛、胸管故障和转为开放脾切除术),均为手术并发症;无治疗相关死亡。

关键数值与推荐

  • 主要结局为达到围手术期血小板计数目标(大手术前90×10^9/L或小手术前45×10^9/L)且未接受挽救治疗。
  • 非劣效性界值为-10%。
  • 艾曲泊帕用法:术前21天至术后第7天口服每日50mg,允许根据血小板计数每周调整剂量。
  • 免疫球蛋白用法:术前7天给予1g/kg或2g/kg静脉注射。

临床怎么用

  • 作者认为艾曲泊帕是免疫性血小板减少症围手术期治疗中静脉注射免疫球蛋白的有效替代方案。
  • 作者指出艾曲泊帕治疗可能增加血栓风险。
  • 作者认为选择何种治疗取决于患者偏好、资源限制、成本和个体风险特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with immune thrombocytopenia are at risk of bleeding during surgery, and intravenous immunoglobulin is commonly used to increase the platelet count. We aimed to establish whether perioperative eltrombopag was non-inferior to intravenous immunoglobulin. METHODS: We did a randomised, open-label trial in eight academic hospitals in Canada. Patients were aged at least 18 years, with primary or secondary immune thrombocytopenia and platelet counts less than 100 × 109 cells per L before major surgery or less than 50 × 109 cells per L before minor surgery. Previous intravenous immunoglobulin within 2 weeks or thrombopoietin receptor agonists within 4 weeks before randomisation were not permitted. Patients were randomly assigned to receive oral daily eltrombopag 50 mg from 21 days preoperatively to postoperative day 7 or intravenous immunoglobulin 1 g/kg or 2 g/kg 7 days before surgery. Eltrombopag dose adjustments were allowed weekly based on platelet counts. The randomisation sequence was generated by a computerised random number generator, concealed and stratified by centre and surgery type (major or minor). The central study statistician was masked to treatment allocation. The primary outcome was achievement of perioperative platelet count targets (90 × 109 cells per L before major surgery or 45 × 109 cells per L before minor surgery) without rescue treatment. We did intention-to-treat and per-protocol analyses using an absolute non-inferiority margin of -10%. This trial is registered with ClinicalTrials.gov, NCT01621204. FINDINGS: Between June 5, 2013, and March 7, 2019, 92 patients with immune thrombocytopenia were screened, of whom 74 (80%) were randomly assigned: 38 to eltrombopag and 36 to intravenous immunoglobulin. Median follow-up was 50 days (IQR 49-55). By intention-to-treat analysis, perioperative platelet targets were achieved for 30 (79%) of 38 patients assigned to eltrombopag and 22 (61%) of 36 patients assigned to intravenous immunoglobulin (absolute risk difference 17·8%, one-sided lower limit of the 95% CI 0·4%; pnon-inferiority=0·005). In the per-protocol analysis, perioperative platelet targets were achieved for 29 (78%) of 37 patients in the eltrombopag group and 20 (63%) of 32 in the intravenous immunoglobulin group (absolute risk difference 15·9%, one-sided lower limit of the 95% CI -2·1%; pnon-inferiority=0·009). Two serious adverse events occurred in the eltrombopag group: one treatment-related pulmonary embolism and one vertigo. Five serious adverse events occurred in the intravenous immunoglobulin group (atrial fibrillation, pancreatitis, vulvar pain, chest tube malfunction and conversion to open splenectomy); all were related to complications of surgery. No treatment-related deaths occurred. INTERPRETATION: Eltrombopag is an effective alternative to intravenous immunoglobulin for perioperative treatment of immune thrombocytopenia. However, treatment with eltrombopag might increase risk of thrombosis. The decision to choose one treatment over the other will depend on patient preference, resource limitations, cost, and individual risk profiles. FUNDING: GlaxoSmithKline and Novartis.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Arnold DM, Heddle NM, Cook RJ, et al. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematol. 2020. PMID: 32853584. doi:10.1016/S2352-3026(20)30227-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。